# IMMUNO-BIL (NCT03704480)

> Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03704480
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions: Advanced Biliary Tract Carcinoma
- Interventions: Durvalumab; Tremelimumab
- Enrollment: 106
- Primary outcome: Overall Survival (OS) in amended Arm A

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=immuno-bil-nct03704480